Overview of pharmacotherapy targeting COVID-19 disease based on ACE-2: current challenges and future directions.
Herz
; 2022 Nov 04.
Article
in English
| MEDLINE | ID: covidwho-2103842
ABSTRACT
The new Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) triggered the pandemic of COVID-19, which is currently still ongoing. In 2021 a worldwide vaccine campaign was launched, and in parallel the lines of research are continuing to target the most effective drug therapies for the treatment of COVID-19 disease. SARS-CoV2 enters host cells via glycoprotein angiotensin-converting enzyme 2 (ACE-2), which plays a major role in renin-angiotensin system interactions and undergoes changes in expression during metabolic and viral diseases, including COVID-19. It seems that the severe lung damage that occurs in several cases of COVID-19 disease may be connected to a deregulated expression of ACE2. In this manuscript we focus on the line of research that studies the pharmacological modification of ACE2 expression, a promising weapon to counter the severe harms caused by COVID-19.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Topics:
Vaccines
Language:
English
Year:
2022
Document Type:
Article
Affiliation country:
S00059-022-05142-6
Similar
MEDLINE
...
LILACS
LIS